No Data
Tibet Nordicang Pharmaceutical Co., Ltd. Report for the third quarter of 2024
Express News | A-share dividends, cash dividends and bonus shares: 3 stocks have equity registration today.
Tibet Rhodiola Pharmaceutical Holding Semi-annual Report for 2023
Summary of Tibet Rhodiola Pharmaceutical Holding's H1 2024 report.
Tibet Pharmaceutical (600211): Sales of neovactin are growing rapidly
Incident: The company released its 2023 annual report, achieving annual revenue of 3.13 billion yuan, +22.7% year-on-year, and realized net profit of 800 million yuan, +116.6% year-on-year, net profit of 780 million yuan after deducting non-return to mother net profit of 780 million yuan, year-on-year.
Tibet Pharmaceutical (600211): New actin production capacity is about to be released, negative effects will be released, and a light package will be launched
Performance: In 2023, we achieved revenue of 3.13 billion yuan (+22.9%), net profit of 80 million yuan (+116.6%) to mother, and net profit of 780 million yuan (+112.5%) after deducting non-net profit. Selling expenses 17.57